JP2023553117A - 顆粒球マクロファージコロニー刺激因子の製造 - Google Patents

顆粒球マクロファージコロニー刺激因子の製造 Download PDF

Info

Publication number
JP2023553117A
JP2023553117A JP2023535012A JP2023535012A JP2023553117A JP 2023553117 A JP2023553117 A JP 2023553117A JP 2023535012 A JP2023535012 A JP 2023535012A JP 2023535012 A JP2023535012 A JP 2023535012A JP 2023553117 A JP2023553117 A JP 2023553117A
Authority
JP
Japan
Prior art keywords
infection
csf
copper
patient
recombinant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553117A5 (https=
Inventor
ミラー、グレッグ
リリー、ショーン
アイアランド、ジェイソン
Original Assignee
パートナー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パートナー セラピューティクス インコーポレイテッド filed Critical パートナー セラピューティクス インコーポレイテッド
Publication of JP2023553117A publication Critical patent/JP2023553117A/ja
Publication of JP2023553117A5 publication Critical patent/JP2023553117A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023535012A 2020-12-08 2021-12-07 顆粒球マクロファージコロニー刺激因子の製造 Pending JP2023553117A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063122593P 2020-12-08 2020-12-08
US63/122,593 2020-12-08
US202163271444P 2021-10-25 2021-10-25
US63/271,444 2021-10-25
PCT/US2021/062168 WO2022125523A1 (en) 2020-12-08 2021-12-07 Manufacture of granulocyte macrophage-colony stimulating factor

Publications (2)

Publication Number Publication Date
JP2023553117A true JP2023553117A (ja) 2023-12-20
JP2023553117A5 JP2023553117A5 (https=) 2024-12-17

Family

ID=81974806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535012A Pending JP2023553117A (ja) 2020-12-08 2021-12-07 顆粒球マクロファージコロニー刺激因子の製造

Country Status (5)

Country Link
US (1) US20240043486A1 (https=)
EP (1) EP4259774A4 (https=)
JP (1) JP2023553117A (https=)
CA (1) CA3201327A1 (https=)
WO (1) WO2022125523A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543560A (ja) * 2006-07-14 2009-12-10 ノボザイムス，インコーポレイティド 真菌細胞中の遺伝子発現を上昇させる方法
WO2015143512A2 (en) * 2014-03-23 2015-10-01 Advantech Bioscience Farmacêutica Ltda. Enhancement of recombinant protein expression with copper
JP2017500017A (ja) * 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
CN101031323A (zh) * 2004-07-16 2007-09-05 尼克塔治疗亚拉巴马公司 Gm－csf部分与聚合物的缀合物
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543560A (ja) * 2006-07-14 2009-12-10 ノボザイムス，インコーポレイティド 真菌細胞中の遺伝子発現を上昇させる方法
JP2017500017A (ja) * 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
WO2015143512A2 (en) * 2014-03-23 2015-10-01 Advantech Bioscience Farmacêutica Ltda. Enhancement of recombinant protein expression with copper

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOPROCESS BIOSYST ENG, vol. 30, JPN6025049133, 2007, pages 305 - 312, ISSN: 0005743895 *
CLINICAL IMMUNOLOGY, vol. 210, JPN6025049129, 2020, pages 108292, ISSN: 0005743893 *
PARTNER THERAPEUTICS, PARTNER THERAPEUTICS ANNOUNCES INITIATION OF CLINICAL TRIAL TO EVALUATE LEUKINE IN RESPIRATORY ILLNE, JPN6025049131, May 2020 (2020-05-01), ISSN: 0005743894 *

Also Published As

Publication number Publication date
CA3201327A1 (en) 2022-06-16
US20240043486A1 (en) 2024-02-08
WO2022125523A1 (en) 2022-06-16
EP4259774A4 (en) 2024-12-04
EP4259774A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
Herman et al. Characterization, formulation, and stability of Neupogen®(Filgrastim), a recombinant human granulocyte-colony stimulating factor
CN107683291B (zh) 针对犬白介素-4受体α的抗体
EP3275894B1 (en) A cxc chemokine receptor 4 (cxcr4) antagonistic polypeptide
AU650893B2 (en) O-glycosylated alpha-2 interferon
CN101255197B (zh) 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
CA3128113A1 (en) Pharmaceutical taci-fc fusion protein formulation
CA3174236A1 (en) Ace2-fc fusion proteins and uses thereof
US20240018499A1 (en) ACE2 Fusion Proteins and Uses Thereof
JP3913273B2 (ja) Ｉｌ−６活性を阻害する合成ペプチド
US20250230210A1 (en) Long-acting granulocyte macrophage-colony stimulating factor
US20240139296A1 (en) Formulations of ace2 fc fusion proteins
KR20080027291A (ko) 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
KR102917813B1 (ko) 수성 약학 제제
US20230242615A1 (en) Fusion polypeptide
JP2023553117A (ja) 顆粒球マクロファージコロニー刺激因子の製造
CN115003686A (zh) 用于抗冠状病毒感染的药物及其应用
US20240182535A1 (en) Granulocyte macrophage-colony stimulating factor mutants
WO2023094571A1 (en) Stabilization of ace2 fusion proteins
KR101789509B1 (ko) 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 생산 방법
CN116710557A (zh) 编码sars-cov-2抗原的优化核苷酸序列
US20250027067A1 (en) Improved ace2 fusion proteins
EP4375293A1 (en) Vhh antibodies against sars-cov-2 omicron variants
KR20190129932A (ko) 폐렴구균 감염의 치료 및 예방을 위한 항-폐렴구균 과다면역 글로불린
US20040229334A1 (en) Process for manufacture of nematode-extracted anticoagulant protein (NAP)
KR101794289B1 (ko) 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 정제 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331